Citations

Clear

3138 citation(s) found for "Smith, AM".

Genetic inactivation of endothelial nitric oxide synthase enhances vasodilator effect of cilostazol
Santhanam, Anantha Vijay R., Hire, Matthew G., Katušić, Zvonimir S. , Smith, Leslie A

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.959.5 Get It

Cilostazol is an inhibitor of phosphodiesterase type III that possesses both antiplatelet and vasodilator effects. The present study aimed to determine the vasodilator effect of cilostazol in eNOS deficient (eNOS −/− ) mice. Mouse aorta was contracted with sub‐maximal concentration of phenylephrine and concentration‐dependent relaxations to cilostazol (10 −8 –10 −5 mol/L) were obtained in aortic rings, isolated from wild type and eNOS −/− mice. As previously reported, in aortas of wild type mice with intact endothelium, relaxations to cilostazol were significantly augmented as compared to aortas without endothelium. Surprisingly, genetic inactivation of eNOS significantly enhanced relaxations to cilostazol suggesting that chronic loss of nitric oxide may unmask compensatory vasodilator mechanisms significantly enhanced by the treatment with cilostazol. The augmentation of relaxations to cilostazol in aortas of eNOS −/− mice was endothelium independent and not inhibited by indomethacin, a cyclooxygenase inhibitor. Our findings support the view that patients suffering from vascular endothelial dysfunction induced by reduced availability of nitric oxide, may exhibit enhanced vasodilator reactivity to cilostazol.
Reduced bioavailability of tetrahydrobiopterin impairs neovascularization after hind limb ischemia
Santhanam, Anantha Vijay R., Katušić, Zvonimir S. , d’Uscio, Livius V. , Smith, Leslie A

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.754.3 Get It

Impaired endothelial function in cardiovascular disorders is mediated, in part, by uncoupling of eNOS caused by reduced availability of tetrahydrobiopterin (BH 4 ). Endothelial progenitor cells (EPCs), originating from bone marrow, contribute to repair of vascular system by either neovascularization following tissue ischemia or re‐endothelialization after endothelial injury. The contribution of BH 4 to the angiogenic function has not been studied. In the present study, we investigated the role of BH 4 in angiogenesis and mobilization of cells enriched in EPCs in hph‐1 mutant mice, a genetic model of GTP‐cyclohydrolase I deficiency. HPLC analysis revealed that enzymatic activity of GTP‐cyclohydrolase I is reduced by 65% in bone marrow of hph‐1 mice (22±4 pmol neopterin/mg/h; P<0.05 vs. wild‐type mice: 63±4 pmol/mg/h). Basal counts of cells co‐expressing CD34 and VEGFR2 (Flk‐1) were reduced in bone marrow and peripheral blood of hph‐1 mice. Fourteen days after hind limb ischemia, recovery of blood flow was significantly reduced in hph‐1 mice as compared to blood flow in ischemic limb of wild type mice. Our findings suggest that reduced bioavailability of BH 4 impairs mobilization of cells enriched in EPCs. This effect may help to explain impaired angiogenesis in hph‐1 mice.
Subarachnoid hemorrhage‐induced cerebral vasospasm stimulates mobilization of circulating progenitor cells
Santhanam, Anantha Vijay R., Katušić, Zvonimir S. , Smith, Leslie A

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.1033.6 Get It

Mobilization of hematopoietic progenitor cells is predictive of functional recovery in stroke. In the present study, alterations in progenitor cell counts were studied in an experimental model of subarachnoid hemorrhage (SAH)‐induced cerebral vasospasm in rabbits. Injection of autologous arterial blood into cisterna magna resulted in significant vasospasm of the basilar arteries forty eight hours following injection. Concomitantly, the number of hematopoietic progenitor cells (CD34 + cells) and CD34 + /Flk‐1 + cells, believed to be enriched in endothelial progenitor cells (EPCs), were significantly increased in the peripheral blood. The levels of the chemokine stromal cell‐derived factor‐1α (SDF‐1α), known to play a key role in the recruitment and retention of CXCR4 + ‐progenitor cells, significantly increased in the plasma of rabbits subjected to SAH. However, levels of SDF‐1α in the cerebrospinal fluid as well as the content of SDF‐1α in the spastic basilar arteries remained unaffected forty eight hours after SAH. In summary, cerebral vasospasm was accompanied by mobilization of hematopoietic progenitor cells and EPCs. We speculate that the pathogenesis of cerebral vasospasm following SAH may be mediated, in part, by impaired recruitment and homing of CXCR4 + ‐ progenitor cells.
Early role for a Na + ,K + -ATPase ( ATP1A3 ) in brain development
Smith, Richard S. , Akula, Shyam K. , Neil, Jennifer E., Wang, Yidi , Hill, Robert , Goldman, Melissa , Mullally, Christopher D. , Reed, Nora , Bello‐Espinosa, Luis , Flores‐Sarnat, Laura , Monteiro, Fabíola Paoli , Casella, Erasmo Barbante , Barkovich, A. James , Gonzalez–Heydrich, Joseph , Florio, Marta , Akula, Shyam K , Wang, Yidi , Bello-Espinosa, Luis , Erasmo, Casella B , Vairo, Filippo , Barkovich, A James , Gonzalez-Heydrich, Joseph , Walsh, Christopher A , Hill, R. Sean, Vairo, Filippo Pinto e , Morava, Éva , Brownstein, Catherine A. , McCarroll, Steven A. , Walsh, Christopher A.

Mayo Clinic

Proceedings of the National Academy of Sciences | June 14, 2021 | Volume: 118 | Issue: 25 | Pages: No page available

10.1073/pnas.2023333118 | PMID 34161264 Get It

Significance By evaluating children with a malformed cerebral cortex, we identified an ATPase pump (ATP1A3) with an early role in brain development. The ATP1A3 pump maintains the physiological concentration of sodium and potassium ions in cells, a process critical for osmotic equilibrium and membrane potential across several developing cell populations. We employed single-cell sequencing approaches to identify key enrichments for ATP1A3 expression during human cortex development. Unravelling this early cell-type–specific pathophysiology in the developing brain offers a potential basis for the treatment of ATP1A3 -related diseases affecting prenatal and early childhood development.
Sinonasal adenocarcinoma: Population‐based analysis of demographic and socioeconomic disparities
Low, Christopher M. , Balakrishnan, Karthik , Smith, Byron M., Stokken, Janalee K., O’Brien, Erin K. , O'Brien, Erin K , Balakrishnan, Karthik , Gompel, Jamie J. Van , Rowan, Nicholas R. , Choby, Garret

Mayo Clinic

Head & Neck | June 12, 2021 | Volume: 43 | Issue: 10 | Pages: 2946-2953

10.1002/hed.26783 | PMID 34117674 Get It

AbstractBackgroundSinonasal adenocarcinoma (SNAC) is a rare tumor. The impact of health disparities on survival, stage at presentation, and utilization of surgery is not well understood in patients with SNAC.MethodsThe Surveillance, Epidemiology, and End Results database was queried for cases of SNAC from 1973 to 2015. Cases were analyzed to assess for disparities in presentation, treatment, and survival.ResultsSNAC was identified in 630 patients. In a multivariate model of overall survival, an age increase of 10 years (Hazard Ratio (HR) = 1.37, p < 0.001), male sex (HR = 1.26, p = 0.045), and more recent decade of diagnosis (HR = 0.74, p < 0.001) were significantly related to time‐to‐death. There is a higher rate of SNAC‐related death in counties with more rural populations (p = 0.027).ConclusionFuture interventions targeting rural and less well‐educated populations may improve care with the goal of increasing the span of healthy life and reducing survival disparities related to SNAC.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Zakharia, Yousef , Rixe, Olivier , Drabick, Joseph J. , Shaheen, Montaser , Grossmann, Kenneth F. , Kolhe, Ravindra , Pacholczyk, Rafał , Sadek, Ramses , Tennant, Lucinda, Link, Charles J., Vahanian, Nicholas N., Brincks, Erik L. , Rossi, Gabriela R. , Munn, David H. , Milhem, Mohammed , McWilliams, Robert R. , Milhem, Mohammed M , Kolhe, Ravindra , Zakharia, Yousef , Smith, Christopher Matthew , Kennedy, Eugene Paul , Yu, Jiayi , Shen, Steven S.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 11, 2021 | Volume: 9 | Issue: 6 | Pages: e002057

10.1136/jitc-2020-002057 | PMID 34117113 Get It

Background The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophan (Trp) and high kynurenine (Kyn) that result from IDO activity. In this study, indoximod was used in combination with a checkpoint inhibitor (CPI) pembrolizumab for the treatment for advanced melanoma. Methods Patients with advanced melanoma were enrolled in a single-arm phase II clinical trial evaluating the addition of indoximod to standard of care CPI approved for melanoma. Investigators administered their choice of CPI including pembrolizumab (P), nivolumab (N), or ipilimumab (I). Indoximod was administered continuously (1200 mg orally two times per day), with concurrent CPI dosed per US Food and Drug Administration (FDA)-approved label. Results Between July 2014 and July 2017, 131 patients were enrolled. (P) was used more frequently (n=114, 87%) per investigator’s choice. The efficacy evaluable population consisted of 89 patients from the phase II cohort with non-ocular melanoma who received indoximod combined with (P). The objective response rate (ORR) for the evaluable population was 51% with confirmed complete response of 20% and disease control rate of 70%. Median progression-free survival was 12.4 months (95% CI 6.4 to 24.9). The ORR for Programmed Death-Ligand 1 (PD-L1)-positive patients was 70% compared with 46% for PD-L1-negative patients. The combination was well tolerated, and side effects were similar to what was expected from single agent (P). Conclusion In this study, the combination of indoximod and (P) was well tolerated and showed antitumor efficacy that is worth further evaluation in selected patients with advanced melanoma.
Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy
Ryder, Mabel , Wentworth, Mark , Garrity, James, Sanders, Jane, Young, Stuart, Furmaniak, Jadwiga , Smith, Bernard Rees , Ryder, Mabel , Algeciras‐Schimnich, Alicia , Morris, John C., Sanders, Paul W.

Mayo Clinic

Thyroid | June 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/thy.2021.0053 | PMID 34114495 Get It

Comparison of Urethral Swabs, Urine, and Urinary Sediment for the Isolation of Chlamydia
Smith, Thomas F., Weed, Lyle A.

Mayo Clinic

Journal of Clinical Microbiology | June 6, 2021 | Volume: 2 | Issue: 2 | Pages: 134-135

10.1128/jcm.2.2.134-135.1975 Get It

In 70 male patients with urethritis, Chlamydia was recovered from 18 urethral swabs (26%), 5 urinary sediments (7%), and 3 urine specimens (4%). All Chlamydia isolates were recovered from urethral swabs.
Identification of a 60-Kilodalton Stress-Related Protein, p60, which Interacts with hsp90 and hsp70
Smith, David F. , Sullivan, W. Patrick, Marion, Tony N. , Zaitsu, Kiyoshi, Toft, David O., Sullivan, William P., Madden, Benjamin J. , McCormick, Daniel

Mayo Clinic

Molecular and Cellular Biology | June 6, 2021 | Volume: 13 | Issue: 2 | Pages: 869-876

10.1128/mcb.13.2.869-876.1993 | PMID 8423808 Get It

The Necessity for Continued Research in Older Renal Transplant Recipients
Smith, Byron, Smith, Byron

Mayo Clinic

Transplantation | June 4, 2021 | Volume: 106 | Issue: 5 | Pages: 917-917

10.1097/tp.0000000000003843 | PMID 34086656 Get It